04/28/21 8:00 AMOTC : CMOPFInvitation to Cosmo's GI Genius(TM) Q&A session for investors, analysts and journalistCosmo Pharmaceuticals N.V. (SIX: COPN) ( XETRA: C43) invites investors, financial analysts as well as business and trade media to a conference call Q&A session on the 4 th of May 2021 to discuss GI Genius (TM), the first device approved by the US Food and DrugRHEA-AIneutral
04/12/21 1:00 AMOTC : CMOPFCosmo announces FDA approval of GI Genius(TM) intelligent endoscopy module, its revolutionary Artificial Intelligence device for lesion detection during colonoscopyCosmo Pharmaceuticals NV (SIX: COPN) today announced the FDA approval of GI Genius(TM) intelligent endoscopy system, its revolutionary device for lesion detection during colonoscopy.The GI Genius module FDA approval marks a pivotal milestone for Cosmo afterRHEA-AIvery positive
03/26/21 7:00 AMOTC : CMOPFCosmo Full-Year Report 2020: Cosmo returns to operating profitCosmo Pharmaceuticals N.V. (SIX: COPN) reports Full-Year results for the year ended 31 December 2020.In 2020, Cosmo received European approval for Methylene Blue MMX (R), received FDA approval for BYFAVO(TM), continued to execute its equity for product strategyRHEA-AIpositive
03/19/21 5:00 AMOTC : CMOPFInvitation to Cosmo's 2020 results / 2021 outlook presentation conference call on 26 March 2021Cosmo Pharmaceuticals NV (SIX: COPN) invites investors, financial analysts and business/lifescience journalists for a telephone conference on 26 March 2021 with CEO Alessandro Della Ch? and CFO Niall Donnelly to discuss the 2020 results and 2021 outlook of theRHEA-AIneutral
